[Form 4] Twist Bioscience Corp Insider Trading Activity

Rhea-AI Filing Summary

Twist Bioscience Corp (TWST) chief financial officer Adam Laponis sold shares to cover tax withholding tied to vested performance stock units. On 10/06/2025 the filing shows a sale of 5,875 shares at $32.187 per share as a mandatory "sell to cover" for tax obligations. After the sale the reporting person beneficially owned 97,042 shares. The form clarifies these were not discretionary trades but sales required under the company's equity plan to satisfy withholding.

Positive

• Transaction disclosed clearly with an explanation the sale was to cover tax withholding
• Reporting person remains a sizable holder with 97,042 shares after the sale

Negative

• Insider sold 5,875 shares, reducing the reporting person's stake
• Sale executed in open market at $32.187, which may marginally increase float

Insights

Equity Compensation Specialist

Sale was a routine sell-to-cover tied to PSU vesting, not necessarily a signal of trading intent.

Sales occurred on 10/06/2025 totaling 5,875 shares at $32.187, reported on a Form 4 executed by an attorney-in-fact. The filing explicitly states the transaction was mandated by the issuer's election under its equity incentive plans to satisfy tax withholding for vested Performance Stock Units.

Dependence rests on the company's plan mechanics: this is a mechanical tax-withholding event rather than an open-market voluntary sale. Investors wanting a near-term indicator can note the remaining holding of 97,042 shares as the observable post-transaction stake.

Corporate Governance Analyst

Officer-level execution with formal signature and disclosure meets regulatory expectations.

The form was signed by an attorney-in-fact on 10/08/2025, shows the reporting person as Chief Financial Officer and files as an individual Form 4. The explanatory remark documents the company's required "sell to cover" policy, providing transparency on motive for the sale.

Material items to observe are any future Form 4 entries showing discretionary trades or changes in equity-plan elections; this single, explained transaction is routine within executive compensation administration.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Laponis Adam

(Last) (First) (Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BLVD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/06/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/06/2025		S		5,875(1)	D	$32.187	97,042	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance Stock Units ("PSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

Remarks:

	/s/ Kendra Fox, as Attorney-in-Fact for Adam Laponis	10/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Twist Bioscience CFO Adam Laponis report on Form 4 (TWST)?

The filing reports a sale of 5,875 shares on 10/06/2025 at $32.187 to satisfy tax withholding from vested Performance Stock Units; post-transaction beneficial ownership is 97,042 shares.

Was the sale by the reporting person discretionary?

No; the Form 4 states the sale was a required "sell to cover" under the issuer's equity incentive plans to satisfy tax withholding obligations and not a discretionary trade.

When was the Form 4 signed and filed for this transaction?

The signature block shows the form signed by an attorney-in-fact on 10/08/2025.

How many shares did the CFO own after the reported transaction?

Following the sell-to-cover transaction the reporting person beneficially owned 97,042 shares.

What price per share was reported for the sale?

The reported sale price was $32.187 per share.